Effect of warnings in a medical journal on the use of orphenadrine

Journal of Evaluation in Clinical Practice

Volumn 14, Issue 4, 2008, Pages 615-617

  Gjerden, På ^a   Bramness, Jørgen G ^b   Slørdal, Lars ^c  

^a TELEMARK HOSPITAL   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; ARIPIPRAZOLE; BENZATROPINE; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; METIXENE; NEUROLEPTIC AGENT; NON PRESCRIPTION DRUG; OLANZAPINE; ORPHENADRINE; PROCYCLIDINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; TRIHEXYPHENIDYL; ZIPRASIDONE;

ARTICLE; AUTOPSY; CAUSE OF DEATH; COMPARATIVE STUDY; DEATH; DENMARK; DRUG APPROVAL; DRUG FATALITY; DRUG MARKETING; DRUG OVERDOSE; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HEALTH CARE PERSONNEL; HUMAN; MEDICAL LITERATURE; NORWAY; PARKINSON DISEASE; PHYSICIAN; PRIORITY JOURNAL; SWEDEN;

ANTIPARKINSON AGENTS; CHOLINERGIC ANTAGONISTS; DRUG INDUSTRY; DRUG UTILIZATION; HUMANS; ORPHENADRINE; PERIODICALS AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS;

EID: 64549134700     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2007.00912.x     Document Type: Article

References (11)

1. Angell, M. (2004) The Truth about the Drug Companies: How They Deceive Us and What to Do about It. New York: Random House.
2. Oxman, A. D., Thomson, M. A., Davis, D. A. & Haynes, R. B. (1995) No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. Canadian Medical Association Journal, 153, 1423-1431.
3. Davis, D. A., Thomson, M. A., Oxman, A. D. & Haynes, R. B. (1992) Evidence for the effectiveness of CME: a review of 50 randomized controlled trials. Journal of the American Medical Association, 268, 1111-1117.
4. Gjerden, P. & Slørdal, L. (1998) The clinical pharmacology of anticholinergic antiparkinsonian drugs: a review with emphasis on acute toxicity. Tidsskrift for Den Norske Lœgeforening, 118, 53-55.
5. Gjerden, P., Engelstad, K. S., Pettersen, G. & Slørdal, L. (1998) Fatalities caused by anticholinergic antiparkinsonian drugs: a retrospective study of a series of Norwegian cases. Tidsskrift for Den Norske Lœgeforening, 118, 42-44.
6. Buckley, N. & McManus, P. (1998) Fatal toxicity of drugs used in the treatment of psychotic illnesses. British Journal of Psychiatry, 172, 461-464.
7. Slørdal, L. & Gjerden, P. (1999) Orphenadrine. British Journal of Psychiatry, 174, 275-276.
8. Gjerden, P. & Slørdal, L. (1999) Livsfarlig psykiatrisk praksis. Tidsskrift for Den Norske Lœgeforening, 119, 1335-1336.
9. Roughead, E. E., Gilbert, A. L. & Primrose, J. G. (1999) Improving drug use: a case study of events which led to changes in use of flucloxacillin in Australia. Social Science and Medicine, 48, 845-853.
10. Dormuth, C. R., Maclure, M., Basset, K., Jauca, C., Whiteside, C. & Wright, J. M. (2004) Effect of periodic letters on evidence-based drug therapy on prescribing behaviour: a randomized trial. Canadian Medical Association Journal, 171, 1057-1061.
11. Figueiras, R., Sastre, I. & Gestal-Otero, J. J. (2001) Effectiveness of educational interventions on the improvement of drug prescription in primary care: a critical literature review. Journal of Evaluation in Clinical Practice, 7 (2), 223-241.